Year: 2020

news_6

Takeda Announces U.S. FDA Breakthrough Therapy Designation Granted for Pevonedistat for the Treatment of Patients with Higher-Risk Myelodysplastic Syndromes (HR-MDS)

– Designation Based on Phase 2 Data and Reinforces Significant Treatment Need for HR-MDS – – Pevonedistat Could be First...